Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAIV H5N2
- Development stage
- Phase 1
- Lead developer
- BioDiem
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
LAIV H5N2 is a live attenuated influenza vaccine (LAIV) developed as a candidate for pre-pandemic protection against the H5N2 subtype of avian influenza virus. This vaccine is cold-adapted, meaning it is designed to replicate efficiently in the cooler temperatures of the upper respiratory tract (nasopharynx) but not in the warmer lower respiratory tract, thereby reducing the risk of severe illness while still eliciting an immune response. It aims to stimulate both humoral (antibody-mediated) and cellular immune responses against the H5 hemagglutinin and N2 neuraminidase surface glycoproteins of the influenza virus. Clinical trials have demonstrated its safety, tolerability, and immunogenicity in healthy adult volunteers.
- Other names
- H5N2 live attenuated influenza vaccineH-5N2 live attenuated influenza vaccineH 5N2 live attenuated influenza vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)
Beyond the preview
Go deeper on LAIV H5N2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAIV H5N2.